Breaking News

You are here » Indian-Commodity  :  Top News  :  Lupin's JV completes global Phase III clinical trial of Etanercept biosimilar

08-Feb2018

Lupin's JV completes global Phase III clinical trial of Etanercept biosimilar

Lupin's joint venture (JV) YL Biologics (YLB) has successfully completed global Phase III clinical trial of its investigational Etanercept biosimilar (YLB113). The Phase III study of YLB113 was a multinational randomized double-blind controlled trial of 52 weeks duration which included more than 500 patients with rheumatoid arthritis (RA) in 11 countries. It compared YLB113's efficacy and safety directly against Enbrel (of Amgen/Pfizer) which has a global market of $11 billion (IQVIA MAT Q3 2017), and is a widely successful biologic agent globally used for the treatment of multiple autoimmune disorders including RA. YLB is a joint venture between the company and Yoshindo in Japan.

The primary endpoint was an equivalent improvement in the rheumatoid arthritis, as measured by American College of Rheumatology 20 (ACR20) response rate. The ACR20 response rate of YLB113 has been found to be within a pre-defined equivalence margin that is expected by most advanced regulatory agencies for marketing authorization. In addition, safety and immunogenicity (antibody formation) of YLB113 was also found to be similar to Enbrel indicating therapeutic equivalence.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.


Related News

View all news

Crude oil futures end higher on Monday

Crude oil futures ended higher for second straight session on Monday amid speculation about a likely drop in demand due to the impact of the US-China trade dispute on global economic growth. President......

Barley futures trade higher on good demand

Barley futures traded higher on NCDEX, as the participants increased their buying due to good demand from beer making industries amid low stocks position due to fall in supplies.The contract for November......

Nickel futures edge higher on improved demand

Nickel futures edged higher on MCX as participants built up fresh positions, tracking improved demand at the spot market. Further, a firming global trend also fuelled the uptrend.The contract for October......

Top News

View all news

PNB plans to sell non-core assets worth Rs 8,600 crore during FY19

Punjab National Bank (PNB) has recognized various assets, including its housing finance arm, for sale and hopes to realise Rs 8,600 crore from these non-core assets during the current fiscal. Meanwhile,......

SBI launches YONO six-day shopping festival

State Bank of India's (SBI) digital service platform YONO has launched a six-day shopping festival beginning October 16 in which customers using the app for shopping via online portals can avail discounts.......

Victory Paper to set up textile unit in Tamil Nadu

Victory Paper and Boards has received an approval for setting up of textile unit at Karur in the state of Tamil Nadu as a part of diversification of the operations of the company and purchase of 32.73......